Sign in
CRBP Stock Price, Chart, Stats & News
Corbus Pharmaceuticals Holdings, Inc.
Save
Corbus Pharmaceuticals Holdings, Inc. (CRBP) does not currently pay a dividend.
112.57M
Market cap
–
Current P/E
–
Forward P/E
CRBP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -46.69% |
ROE | -65.76% |
D/E | 0.01x |
Interest coverage ratio | – |
CRBP valuation
P/E | – |
P/S | – |
P/B | 0.79x |
P/CF | -1.80x |
P/FCF | -1.69x |
P/OCF | -1.80x |
PEG | 0.17x |
EV multiple | – |
About
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Similar securities
Based on sector and market capitalization
Report issue